Anti-Cancer Drug Design

Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues
pp. 261-270(10)
Authors: McDonald R.W.; Bunjobpon1 W.; Liu T.; Fessler1 S.; Pardo1 O.E.; Freer I.K.A.; Glaser1 M.; Seckl1 M.J.; Robins D.J.

Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro
pp. 271-277(7)
Authors: Xu S.; Chen S.; Zhang M.; Shen T.; Liu1 Z.; Zhao1 Y.; Wu1 Y.

Photokilling of cultured tumour cells by the porphyrin derivative CF3
pp. 279-290(12)
Authors: Villanueva A.; Durantini1 E.N.; Stockert J.C.; Rello S.; Vidania2 R.; Cañete M.; Juarranz A.; Arranz R.; Rivarola3 V.

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
pp. 291-303(13)
Authors: McCluskey A.; Ackland1 S.P.; Gardiner E.; Walkom C.C.; Sakoff1 J.A.

Linker length in podophyllotoxin–acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines
pp. 305-315(11)
Authors: Rothenborg-Jensen1 L.; Hansen4 H.F.; Wessel1 I.; Nitiss3 J.L.; Schmidt24 G.; Jensen2 P.B.; Sehested1 M.; Jensen12 L.H.

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA)
pp. 317-324(8)
Authors: Bridewell D.J.A.; Finlay G.J.; Baguley B.C.

Keyword index
pp. 325-325(1)

Author index
pp. 327-328(2)